Dr Kylie Quinn leads the Ageing and Immunotherapies Group at RMIT University, where her team is developing ways to improve vaccines and cell-based cancer therapies in older patients. As we age, immune cells known as T cells can become more difficult to activate, so her team aim to circumvent this limitation and augment T cell activation. Her award-winning work has defined adjuvancy mechanisms for adenoviral vaccines (JCI 2015) and age-driven changes in gene expression and metabolism across T cell subsets that underpin age-related dysfunction (Cell Rep 2018, Nat Comms 2020). More broadly, Kylie regularly engages in accessible and rigorous science communication and was a key figure communicating on vaccination to the Australian public during the COVID-19 pandemic.